Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
10
2020
accepted:
27
11
2020
entrez:
10
12
2020
pubmed:
11
12
2020
medline:
5
1
2021
Statut:
epublish
Résumé
Italy has been the first Western country to be heavily affected by the spread of SARS-COV-2 infection and among the pioneers of the clinical management of pandemic. To improve the outcome, identification of patients at the highest risk seems mandatory. Aim of this study is to identify comorbidities and clinical conditions upon admission associated with in-hospital mortality in several COVID Centers in Campania Region (Italy). COVOCA is a multicentre retrospective observational cohort study, which involved 18 COVID Centers throughout Campania Region, Italy. Data were collected from patients who completed their hospitalization between March-June 2020. The endpoint was in-hospital mortality, assessed either from data at discharge or death certificate, whilst all exposure variables were collected at hospital admission. Among 618 COVID-19 hospitalized patients included in the study, 143 in-hospital mortality events were recorded, with a cumulative incidence of about 23%. At multivariable logistic analysis, male sex (OR 2.63, 95%CI 1.42-4.90; p = 0.001), Chronic Liver Disease (OR 5.88, 95%CI 2.39-14.46; p<0.001) and malignancies (OR 2.62, 95%CI 1.21-5.68; p = 0.015) disclosed an independent association with a poor prognosis, Glasgow Coma Scale (GCS) and Respiratory Severity Scale allowed to identify at higher mortality risk. Sensitivity analysis further enhanced these findings. Mortality of patients hospitalized for COVID-19 appears strongly affected by both clinical conditions on admission and comorbidities. Originally, we observed a very poor outcome in subjects with a chronic liver disease, alongside with an increase of hepatic damage.
Sections du résumé
BACKGROUND
Italy has been the first Western country to be heavily affected by the spread of SARS-COV-2 infection and among the pioneers of the clinical management of pandemic. To improve the outcome, identification of patients at the highest risk seems mandatory.
OBJECTIVES
Aim of this study is to identify comorbidities and clinical conditions upon admission associated with in-hospital mortality in several COVID Centers in Campania Region (Italy).
METHODS
COVOCA is a multicentre retrospective observational cohort study, which involved 18 COVID Centers throughout Campania Region, Italy. Data were collected from patients who completed their hospitalization between March-June 2020. The endpoint was in-hospital mortality, assessed either from data at discharge or death certificate, whilst all exposure variables were collected at hospital admission.
RESULTS
Among 618 COVID-19 hospitalized patients included in the study, 143 in-hospital mortality events were recorded, with a cumulative incidence of about 23%. At multivariable logistic analysis, male sex (OR 2.63, 95%CI 1.42-4.90; p = 0.001), Chronic Liver Disease (OR 5.88, 95%CI 2.39-14.46; p<0.001) and malignancies (OR 2.62, 95%CI 1.21-5.68; p = 0.015) disclosed an independent association with a poor prognosis, Glasgow Coma Scale (GCS) and Respiratory Severity Scale allowed to identify at higher mortality risk. Sensitivity analysis further enhanced these findings.
CONCLUSION
Mortality of patients hospitalized for COVID-19 appears strongly affected by both clinical conditions on admission and comorbidities. Originally, we observed a very poor outcome in subjects with a chronic liver disease, alongside with an increase of hepatic damage.
Identifiants
pubmed: 33301529
doi: 10.1371/journal.pone.0243700
pii: PONE-D-20-34052
pmc: PMC7728173
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0243700Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet Gastroenterol Hepatol. 2020 May;5(5):428-430
pubmed: 32145190
PLoS One. 2020 Oct 15;15(10):e0239571
pubmed: 33057443
Clin Cardiol. 2020 Dec;43(12):1478-1493
pubmed: 33026120
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2103-2109
pubmed: 33161221
Hepatology. 2020 Aug;72(2):389-398
pubmed: 32359177
IEEE Trans Biomed Eng. 2013 May;60(5):1336-44
pubmed: 23268381
Ann Hepatol. 2020 Nov - Dec;19(6):614-621
pubmed: 32920162
J Stroke Cerebrovasc Dis. 2020 Aug;29(8):104949
pubmed: 32410807
Hypertension. 2020 Aug;76(2):366-372
pubmed: 32564693
Liver Int. 2020 Jun;40(6):1278-1281
pubmed: 32251539
Front Cardiovasc Med. 2020 Oct 09;7:585866
pubmed: 33195473
Eur Respir J. 2020 May 7;55(5):
pubmed: 32269088
Hepatol Commun. 2020 Sep 02;4(12):1758-1768
pubmed: 32838108
Diabetes Care. 2020 Jan;43(Suppl 1):S14-S31
pubmed: 31862745
JAMA Netw Open. 2020 Jun 1;3(6):e2012270
pubmed: 32543702
J Hepatol. 2020 Nov;73(5):1063-1071
pubmed: 32526252
Antioxidants (Basel). 2020 Jul 16;9(7):
pubmed: 32708578
Rev Inst Med Trop Sao Paulo. 2020 Jun 22;62:e43
pubmed: 32578683
BMC Med Res Methodol. 2016 Nov 24;16(1):163
pubmed: 27881078
Am J Transl Res. 2020 Oct 15;12(10):6537-6548
pubmed: 33194050
World J Gastroenterol. 2020 Aug 28;26(32):4753-4762
pubmed: 32921955
Stroke. 2020 Sep;51(9):2674-2682
pubmed: 32755348
Arch Acad Emerg Med. 2020 Sep 12;8(1):e72
pubmed: 33134968
Gastroenterology. 2020 Aug;159(2):768-771.e3
pubmed: 32376408
Gut. 2020 Aug;69(8):1545-1547
pubmed: 32414813
Mol Aspects Med. 2009 Feb-Apr;30(1-2):99-110
pubmed: 18926849
Front Med (Lausanne). 2020 Jul 21;7:458
pubmed: 32793619
Eur J Gastroenterol Hepatol. 2021 Sep 1;33(9):1194-1200
pubmed: 32796355
PLoS One. 2020 Aug 26;15(8):e0238215
pubmed: 32845926
Ann Intern Med. 2020 Aug 4;173(3):204-216
pubmed: 32442035
Anesthesiology. 2020 Jun;132(6):1317-1332
pubmed: 32195705
J Investig Med. 2021 Jan;69(1):75-85
pubmed: 33051358
PLoS One. 2015 Mar 16;10(3):e0122124
pubmed: 25774783
Chest. 2020 Nov;158(5):1992-2002
pubmed: 32681847
Indian J Gastroenterol. 2020 Jun;39(3):285-291
pubmed: 32803716
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
Eur J Clin Invest. 2020 Oct;50(10):e13338
pubmed: 32589264
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Epidemiol Prev. 2020 Sep-Dec;44(5-6 Suppl 2):51-59
pubmed: 33412794
JHEP Rep. 2020 Oct;2(5):100169
pubmed: 32835190
Hepatol Int. 2020 Sep;14(5):701-710
pubmed: 32734407
Am J Pathol. 2006 Apr;168(4):1057-9
pubmed: 16565481
Kidney Int. 2013 Sep;84(3):622-3
pubmed: 23989362
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
J Gerontol A Biol Sci Med Sci. 2020 Sep 16;75(9):1796-1800
pubmed: 32506122